^
    3d
    18F-FAPI & FDG PET/MRI assisting the precise treatment of thyroid-related eye diseases with teprotumumab and evaluating its efficacy, a prospective study (ChiCTR2500113667)
    P=N/A, N=30, Not yet recruiting, Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital
    New trial
    |
    Tepezza (teprotumumab-trbw)
    3d
    Clinical Efficacy of Teprotumumab in the Treatment of Thyroid-Associated Ophthalmopathy: A Multicenter Prospective Real-World Study (ChiCTR2500112460)
    P=N/A, N=550, Not yet recruiting, Eye and ENT hospital of Fudan University; Eye and ENT hospital of Fudan University
    New trial
    |
    Tepezza (teprotumumab-trbw)
    3d
    A prospective, randomized controlled study evaluating the efficacy and safety of Teprotumumab versus glucocorticoids in the treatment of thyroid eye disease patients with dysthyroid optic neuropathy (ChiCTR2500112153)
    P=N/A, N=62, Not yet recruiting, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People’s Hospital, Shanghai Jiao Tong Universit
    New trial
    |
    Tepezza (teprotumumab-trbw)
    3d
    A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Teprotumumab in Thyroid-Associated Ophthalmopathy (TAO) Patients with Clinical Activity Score (CAS) <3 and Radiographically Active Disease (ChiCTR2500111604)
    P=N/A, N=111, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New trial
    |
    Actemra IV (tocilizumab) • Tepezza (teprotumumab-trbw)
    3d
    Evaluation of efficacy and safety of teprotumumab combined with glucocorticoids in the treatment of moderate to severe active thyroid eye disease (ChiCTR2500114188)
    P4, N=30, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
    New P4 trial
    |
    Tepezza (teprotumumab-trbw)
    7d
    A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants (clinicaltrials.gov)
    P1, N=20, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion
    |
    Tepezza (teprotumumab-trbw)
    8d
    Unveiling bioactive compounds in kola nut seeds: GC-MS identification and computational analysis for anticancer potential. (PubMed, Front Nutr)
    From these, 15 bioactive compounds, including scopolin, picropodophyllin, catechin, yohimbine, squalene, campesterin, epicatechin, stigmasterol, p-coumaric acid, quinoline, methyl linoleate, methyl oleate, DTB-spdione, theobromine, and caffeine, were shortlisted for in silico docking studies...Based on enhanced fractionations, our study provides an expanded chemical profile of kola nut seeds and suggests that selected phytochemicals may serve as promising candidates for anticancer drug development. Further experimental validation is warranted to translate these insights into therapeutic applications.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    picropodophyllin (AXL1717)
    19d
    HZNP-TEP-402: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study (clinicaltrials.gov)
    P4, N=313, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion
    |
    Tepezza (teprotumumab-trbw)
    20d
    A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=87, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    27d
    A Phase 1 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1, N=78, Terminated, Fusion Pharmaceuticals Inc. | N=253 --> 78 | Active, not recruiting --> Terminated; A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.
    Enrollment change • Trial termination • First-in-human
    |
    IGF1 (Insulin-like growth factor 1)
    |
    HER-2 negative
    |
    FPI-1434
    1m
    Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease (clinicaltrials.gov)
    P4, N=40, Not yet recruiting, Sheba Medical Center
    New P4 trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=99, Recruiting, Zai Lab (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open